Healthcare ECONOMIST

NOVEMBER 26, 2023

How does the UK spend so little on drugs? Many people focus on the efforts of National Institute for Health and Care Excellence (NICE) and their focus on linking drug prices paid to health value delivered. However, there is another reason why the UK’s total spend on pharmaceuticals is low: price caps.

Pharmaceuticals 75

Pharmaceuticals 75

Health Populi

JUNE 5, 2022

The good news about prescription drugs, in the context of medical spending in the U.S., But there’s bad news about prescription drugs in the context of medical spending in America. This turbocharged a viable market for generic drugs in the U.S., is that 9 in 10 medicines prescribed are generics.

Medicare 149

Medicare Regulations Healthcare Pharmaceuticals 149

Healthcare ECONOMIST

OCTOBER 19, 2023

A Health Affairs Forefront paper by researchers Melanie Whittington, Peter Neumann, Joshua Cohen, and Jonathan Campbell makes a compelling case for incorporating drug price dynamics into cost effectiveness analysis. The first questions many people may have is ‘how do drug prices usually change over time?’

Pharmaceuticals 68

Pharmaceuticals Accountability 68

Healthcare ECONOMIST

FEBRUARY 24, 2023

When you buy a car, there is the sticker price and what you actually paid after haggling with the dealer over discounts. For pharmaceuticals, the media typically reports on list prices which are analogous to the “sticker price” for cars. By 2019, we observe an absolute reduction of −0.2 [95%

Medicare 96

Medicare Pharmaceuticals Medicaid 96

HIT Consultant

NOVEMBER 15, 2022

Many of these treatments are drug-based gene therapies–- but they come with an extremely high price tag. But at what price? When a drug costs some $2.8 And neither can citizens; when the outlay rises, prices for insurance, hospital stays, tests, and even tax rates rise as well.

Hospitals 98

Hospitals Medicare Prevention Healthcare 98

Healthcare ECONOMIST

FEBRUARY 7, 2023

According to a 2022 CBO report , healthcare spending per person is much higher for commercially insured individuals than those insured by Medicare and this difference is largely drive by price differentials. link] Why are the outstanding research questions related to the prices commercial insurers pay providers?

Measurable Quality 92

Measurable Quality Telemedicine Medicare Hospitals 92

HIT Consultant

DECEMBER 14, 2022

Still, that hasn’t stopped game-changers like Cuban’s patient-friendly Cost Plus Drug Company from breaking ground. Innovative companies are springing up with new cost models and new technology – like devices to monitor patient behavior and artificial intelligence to deliver insights from that data.

Patient Experience 98

Patient Experience Nursing Pharmaceuticals Healthcare 98

Healthcare ECONOMIST

APRIL 13, 2023

That is the title of a new USC Schaeffer Center white paper authored by Dana Goldman, Joe Grogan, Darius Lakdawalla, Barry Liden, Kyi-Sin Than, Erin Trish and myself. Bring transparency and a focus on value to the IRA price-determination process. Incentivize the production of new information about effectiveness.

Regulations 68

Regulations Accountability Pharmaceuticals Medicare 68

Healthcare It News

JUNE 10, 2022

For more than 15 years, the country has been served by only one e-prescribing network, Surescripts (which this week appointed Frank Harvey as its new chief executive following the retirement of CEO Tom Skelton.). How does your e-prescribing network work? They then have to call their doctor to discuss more affordable options.

Integration 203

Integration Doctors Pharmaceuticals Healthcare 203

Healthcare ECONOMIST

JANUARY 25, 2022

The book The Right Price: A Value-Based Prescription for Drug Costs is a fantastic book for individuals interested in understanding why value-based drug pricing makes sense. Are high drug prices a good thing? ” The rise of orphan drugs. ” The rise of orphan drugs.

Pharmaceuticals 87

Pharmaceuticals Health Technology Medicaid Healthcare 87

Healthcare ECONOMIST

OCTOBER 30, 2023

In Caremark’s place, Blue Shield of California will contract out the job to five separate companies…Blue Shield of California, or BSCA, expects to save $500 million a year from the move, calling it a “milestone” for a “broken prescription drug system.” PBMs say they help lower drug prices and slow drug spending growth.

Integration 75

Integration Healthcare Pharmaceuticals 75

NASHP

AUGUST 16, 2021

This approach to PBM procurement, first used by New Jersey , aims to achieve savings by encouraging PBMs to be more competitive on pricing in their bidding for contracts without reducing drug benefits for the state’s public employees. Minnesota released an RFP for a technology platform with bids due in early August.

105

105

Health Populi

JUNE 23, 2022

“Inflation is the big story,” the economics team at Morning Consult told us yesterday in a call on “How to Think Like An Economist.” An hour after the Morning Consult session, I brainstormed the topic of consumers-as-payers of medical bills and prescription drugs with GoodRx strategy leaders. in the U.S.

Accountability 115

Accountability Medicare Hospitals Healthcare 115

Health Populi

JANUARY 24, 2023

.” These two programs come from outside of the legacy health care system of so-called incumbents — hospitals, health systems, health insurance — leveraging two brand-names beloved to many consumers for convenience, price transparency, and sheer cost. First, check out Amazon Pharmacy’s RxPass.

Hospitals 68

Hospitals Healthcare 68

Health Populi

JULY 24, 2023

The retail health landscape continues to grow, now with GNC Health offering a new program featuring telehealth and “curated set” of 40+ generic prescription drugs commonly used in urgent care settings. ” Here’s how GNC gets to the $400 in benefits. for one year’s membership.

Urgent Care 118

Urgent Care Healthcare Primary Care Quality of Care 118

NASHP

NOVEMBER 1, 2021

Prescription Drug Pricing Transparency Law Comparison Chart Updated November 1, 2021. To learn more about how states are implementing transparency laws and reporting on high drug prices, explore the Center for State Rx Drug Pricing’s Administrative Action tracker.

58

58

NASHP

DECEMBER 18, 2023

Prescription Drug Affordability Boards (PDABs) are independent entities established to analyze the high cost of drugs and to identify effective ways to lower cost in order to increase access to affordable drugs for consumers. 1 What is the purpose of the Colorado Prescription Drug Affordability Board?

Pharmaceuticals 52

Pharmaceuticals 52

HIT Consultant

MARCH 22, 2023

Paul Ketchel, CEO of MDsave Over two years have passed since the hospital price transparency rule was enacted. Unfortunately, America still struggles with high, painfully opaque pricing across healthcare that hurts employers, workers, patients, and taxpayers. At the same time, 100 million Americans find themselves in healthcare debt.

Healthcare 97

Healthcare Patient Experience Hospitals Medicaid 97

NASHP

AUGUST 11, 2022

Q&A on NASHP’s Model Act to Reduce the Cost of Prescription Drugs by Establishing a Prescription Drug Affordability Board. In 2017, the National Academy for State Health Policy (NASHP) released model legislation to enable states to address high drug costs by creating a Prescription Drug Affordability Board (PDAB).

Pharmaceuticals 52

Pharmaceuticals Prevention Regulations Accountability 52

Healthcare ECONOMIST

MAY 20, 2022

Last month, ICER updated their protocol for identifying drugs that have unsupported price increases (UPI). ICER says that the UPI reports are not intended to determine whether a price increase for a drug is fully justified by new clinical evidence or meets an ICER health-benefit-based price benchmark.

Medicare 58

Medicare Health Data Pharmaceuticals 58

Healthcare It News

SEPTEMBER 12, 2022

Healthcare IT News sat down with Weisberg to discuss what telehealth cannot do to cure the therapist shortage, how virtual reality works in mental healthcare, why she believes VR is the goldilocks answer to the staffing problem, and how virtual reality can give access to alternatives to pharmacological treatments like opioids.

Physical Therapy 240

Physical Therapy Healthcare Health Technology 240

Healthcare ECONOMIST

JULY 27, 2022

A paper by Gracia, David and Conti (2022) in Health Affairs Forefront poses the question ‘how do financial incentives impact venture capitalist’s (VC) investment decisions in early-stage biotech companies, and ultimately innovation?’ Based on these interviews, the authors had 7 key findings.

Pharmaceuticals 65

Pharmaceuticals 65

Healthcare ECONOMIST

AUGUST 29, 2021

It stands to reason that policies that aim to reduce drug prices or squeeze life science companies profits are likely to decrease incentives to finance the research and development needed to bring a drug to market. The timing of the impact of such a policy on drug development is shown graphically below. after 18 years.

Life Sciences 64

Life Sciences Pharmaceuticals Medicare Accountability 64

HIT Consultant

NOVEMBER 8, 2022

Currently, some 22 states have enacted prescription drug transparency laws that require entities across the drug supply chain to report pricing information to state officials. This trend is also confirmed by a 2021 GoodRx survey around medication adherence and drug cost, which shows that 18.7%

Pharmaceuticals 52

Pharmaceuticals Life Sciences Law Firms Regulations 52

Bill Of Health

NOVEMBER 17, 2022

Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study. New Federal Incentives for Diversity in Clinical Trials.

Regulations 73

Regulations Medicaid Medicare Pharmaceuticals 73

Health Advances

OCTOBER 31, 2022

After two years of regulatory back and forth and debates around the drug’s efficacy, Amylyx Pharmaceuticals’ new Amyotrophic Lateral Sclerosis (ALS) treatment, Relyvrio (sodium phenylbutyrate/taurursodiol), was approved by the FDA on September 29, 2022. By Olivia Novins, Michael Davitian, Carrie Jones. Relyvrio’s Approval Process.

Pharmaceuticals 52

Pharmaceuticals Life Sciences Medicaid Healthcare 52

HIT Consultant

JANUARY 23, 2023

What You Should Know: – As the world prepares for the Inflation Reduction Act’s landmark policy changes, healthcare stakeholders realize that its wide-ranging effects will require new approaches to drug pricing, health plan design, and investment. Stakeholders can best influence these policies before drafts are published.

Healthcare 52

Healthcare Medicare Medicaid 52

HIT Consultant

JANUARY 10, 2024

At any given time, 300 or more drugs bloat the FDA’s shortage list. Many of these medicines, including life-saving cancer drugs , don’t get to the patients who need them. Drug shortages have a variety of causes, including contamination at pharmaceutical plants, major storms, supply chain issues, or runs on important vaccines.

Hospitals 59

Hospitals Pharmaceuticals Nursing Prevention 59

NASHP

JANUARY 10, 2022

Drug price transparency laws enable state policymakers to understand opaque drug pricing and payment systems to formulate appropriate policy solutions to high prices, while also creating the data infrastructure to effectively realize those policy solutions. Current State Transparency Landscape .

Accountability 63

Accountability Medicaid Medicare 63

HIT Consultant

OCTOBER 25, 2022

The costs for drug discovery and development are skyrocketing, but AI (artificial intelligence) is introducing new efficiencies to help find effective treatments faster. AI can speed up the processes of collecting and accessing information to drastically shorten drug development time to keep the price of drug development in check.

Pharmaceuticals 98

Pharmaceuticals Regulations Doctors Health Technology 98

Healthcare ECONOMIST

FEBRUARY 21, 2022

I previously covered research from Dickson and Kent (2021) that examined how the entry of generic drugs impacts the price Medicare pays. mean price reduction in the bundled ASP, 2 generic competitors were associated with a 32.7% mean price reduction, and 3 generic competitors were associated with a 52.0%

Medicare 55

Medicare Pharmaceuticals 55

NASHP

NOVEMBER 29, 2022

An Act to Reduce Prescription Drug Costs Using Reference-Based Pricing November 29, 2022. The purpose of this Chapter is to protect the safety, health, and economic well-being of [Name of State] residents by safeguarding them from the negative and harmful impact of excessive and unconscionable prices for prescription drugs.

Regulations 52

Regulations Prevention Medicare 52

NASHP

NOVEMBER 7, 2022

NASHP Releases Model State Legislation to Lower the Cost of Prescription Drugs November 7, 2022 / by Drew Gattine and Kris Vallecillo. Rising prescription drug prices drive up overall health care costs and increase out of pocket spending for consumers. In 2017, NASHP released its first model bill to create a state-based PDAB.

Medicare 52

Medicare Prevention 52

Health Populi

JUNE 24, 2021

With growing global supply and competition, we can expect prices for COVID-19 vaccines to fall, anticipating additional volumes from Sinopharm, Moderna, Sinovac, Gamaleya Institute, among others. We also expect innovation to come out of pharma and biotech labs, and who will pay for new-new therapies?

Healthcare 108

Healthcare Pharmaceuticals Population Health Regulations 108

Healthcare ECONOMIST

DECEMBER 8, 2021

Since the passage of the Orphan Drug Act in 1983, progress has been made in researching and developing drugs for the 7,000 rare diseases currently identified by scientists, but many diseases still lack adequate therapies, preventing patients from accessing new innovations. . A summary of the topic and the speaker list are below.

Pharmaceuticals 77

Pharmaceuticals Prevention Hospitals Healthcare 77

Health Populi

AUGUST 2, 2021

This has raised the importance of price transparency, which is based on the hypothesis that if patients had access to personally-relevant price/cost information from doctors and hospitals for medical services, and pharmacies and PBMs for prescription drugs, the patient would behave as a consumer and shop around. In the U.S.,

Doctors 129

Doctors Patient Experience Medical Services Hospitals 129

Health Populi

APRIL 25, 2023

The latest Health Care Cost and Utilization Report from the Health Care Cost Institute (HCCI) details health spending in 2021, dissecting the change in terms of utilization of services and prices by category. Outpatient spending comprised just over $1 in $4 per capita, followed by prescription drugs which were allocated over $1 of every $5.

Ambulatory Care 62

Ambulatory Care Hospitals Healthcare 62